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Depression has become one of the most prominent problems in society, disrupting both 
personal and social lives. Tricyclic antidepressants (TCAs) were first developed in the 
1950’s and became some of the leading anti-depressant medications on the market later 
that decade. Today, newer anti-depressants have risen to the forefront, being safer and 
having a lower side-effect probability. Nonetheless, TCAs continue to be prescribed for 
severe depression, especially in cases where the newer anti-depressants have failed. 
However, TCAs are still highly potent, the toxicity associated with these compounds 
cannot be ignored. They have considerable cardiovascular and neurological toxicity, and 
in the event of an overdose, may lead to death within an hour. In an effort to identify the 
concentration of these TCAs in individuals, an LC-MS/MS method was developed and 
validated for the analysis of amitriptyline, desipramine, imipramine, and nortriptyline in 
human plasma samples. The method was developed and validated on two different LC-
MS/MS instruments, ABSciex QTRAP 3200 and ABSciex QTRAP 4500. Two specific 
MRM transitions for amitriptyline, desipramine, imipramine, and nortriptyline, and two 
specific MRM transitions for amitriptyline-d3, desipramine-d3, imipramine-d3, and 
nortriptyline-d3 internal standards, were monitored for each compound for maximum 
selectivity and sensitivity. Separation was achieved on a Synergi Hydro-RP column (150 
x 3.00 mm; 4 µm; 80 Å), and data acquisition and processing were performed with 
AnalystTM 1.6.3 software. The extraction procedure was developed to be rapid and simple, 
involving crashing the plasma with cold acetonitrile (ACN), filtering through a 0.2 μ 
polypropylene (PP) filter, evaporation, and reconstitution. The limit of detection (LOD) 
and limit of quantitation (LOQ) were identified to be 1 ng/mL, and the upper limit of 
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linearity (uLOL) was determined to be 400 ng/mL. The developed method was applied to 
more than 350 human plasma samples. Matrix effect and drug interference studies were 
carried out, and neither matric effect nor drug interference was observed in any of the 
samples. The developed and validated LC-MS/MS method was robust, reproducible, and 
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Depression and anxiety have been two of the most common and prevalent problems in 
society for decades; accordingly, several antidepressants have been introduced into the 
market for years, with imipramine introduced in Europe in 1958 and in the United States 
in 1959 (Lowry, 2012). After imipramine was marketed, amitriptyline and nortriptyline 
followed soon after in 1961 (Fangmann et al., 2008) and in 1964 (Drugs.com, 2020), 
respectively. Amitriptyline was the 88th most prescribed medication in the US, with over 8 
million prescriptions, and nortriptyline was the 192nd most prescribed medication in the US 
with over 3.1 million prescriptions in 2016 (clincalc.com, 2019), indicating the prevalence 
of these medications in the general public. 
Amitriptyline, desipramine, imipramine, and nortriptyline are all classified as 
tricyclic antidepressants (TCAs) and are commonly used to treat a multitude of mental 
illnesses, including depression (Brunton, Chabner, and Knollman, 2010), attention-deficit 
hyperactivity disorder (ADHD) and bipolar disorder, and anxiety (BNF 76 (76 ed.), pg. 
374, 2018, Leucht et al., 2012, Ghanizadeh, 2013, Skidmore-Roth, 2010). Newer, more 
effective, and safer alternatives to these four TCAs have been developed; however, these 
TCAs are still the most commonly used antidepressants on the market. Accompanying the 
use of these TCAs come several possible side-effects, including dry mouth, constipation, 
weakness, drowsiness, and blurred vision (Drugs.com, 2020, Martindale: The Complete 
Drug Reference, 2013). Consequently, these compounds have a higher abuse potential, 
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necessitating the development of an efficient and simple method for the detection of these 
TCAs in human plasma.  
In this thesis, we report the development and validation of a LC-MS/MS method 
for the identification and quantitation of the four TCAs, amitriptyline, desipramine, 
imipramine, and nortriptyline (Figure 1) in human plasma. The highly sensitive method 
was developed on two instruments, ABSciex QTRAP 3200 and ABSciex QTRAP 4500, 
and is able to analyze these TCAs to low concentrations, with an LOD and LOQ of 1.0 
ng/mL and ULOL of 400 ng/mL in the samples tested. The extraction method is simple, 
easy, and reproducible, requiring minimal sample preparation. The validated method was 
used to quantitate the concentrations of TCAs in over 350 human plasma samples. This 
method is simple and reproducible for the quantitation of amitriptyline, desipramine, 





















Figure 1: Chemical Structures of Amitriptyline, Desipramine, Imipramine, and 






Instrumentation and LC Conditions 
 
The Applied Biosystems/MSD Sciex (ABSciex) QTRAP 3200 LC-MS/MS system 
uses a Shimadzu Prominence HPLC, while the ABSciex QTRAP 4500 LC-MS/MS system 
uses a Nexera UPLC. Both systems utilize a dual pump, a vacuum solvent microdegasser, 
a controlled-temperature autosampler, and an MS-MS detector (QTRAP 3200 or QTRAP 
4500 with a turbo-ion ESI source operating the positive-ion multiple reaction monitoring 
(MRM) mode). Specific MRM transitions were monitored for each compound for 
maximum selectivity and sensitivity. Separation was achieved on a Synergi Hydro-RP 
column (150 mm x 3.00 mm; 4 µm; 80 Å) from Phenomenex (Torrance, CA, USA). Data 
acquisition and processing were performed with AnalystTM 1.6.3 software (Applied 
Biosystems (AB Sciex), Foster City, CA). 
 
Standards and Reagents 
 
Two tricyclic antidepressant mix solutions were prepared at two different 
concentrations: 0.5 μg/mL and 2.0 μg/mL. The TCAs mix solutions were prepared from a 
combination of four standards (Cerilliant), namely amitriptyline, desipramine, imipramine, 




Internal Standard Preparation  
 
A d3-tricyclic antidepressant mix solution was prepared, at 4.0 μg/mL. The internal 
standard mix solution was prepared from a combination of four internal standards 
(Cerilliant), namely amitriptyline-d3, desipramine-d3, imipramine-d3, and nortriptyline-d3. 




For calibrators, appropriate amounts of each drug (depending on concentration of 
the calibrator), internal standard (IS), and 250 μL of blank plasma (BioChemed Service 
Winchester, VA) were spiked and aliquoted into pre-labeled extraction tubes. For the 
negative control, 250 μL of blank plasma and the appropriate amount of IS were aliquoted 
and spiked into a pre-labeled extraction tube. All of these tubes were vortexed.  
The unextracted sample was prepared by spiking appropriate amounts of the 
standard drug solution and IS into a pre-labeled HPLC vial. For unknown samples, 250 μL 
of each sample was aliquoted into appropriately pre-labeled extraction tubes, followed by 
spiking the appropriate amount of IS. The proteins were crashed by adding 500 μL of ice-
cold acetonitrile (ACN). The tubes were vortexed for 1 minute, followed by centrifugation 
for 3 minutes. The surface layers from each tube were decanted into separate, pre-labeled 
1 mL syringes attached to 0.2 μ PP (polypropylene) syringe filters. The surface layers were 
then filtered into pre-labeled extraction tubes and evaporated to completion under N2 (g). 
The samples were reconstituted with 100 μL of 0.5N HCl in methanol and vortexed. Then, 
cotton balls were used to filter each reconstitute into HPLC vial inserts placed in separate, 




The LC-MS/MS method was validated at 2 concentrations (40 ng/mL and 120 
ng/mL) with 6 replicates each for amitriptyline, desipramine, imipramine, and nortriptyline 
over a period of 3 days with one 6-point calibration curve (25, 50, 100, 200, 300, and 400 
ng/mL).  The accuracy was calculated using the standard addition method. The LOD, LOQ, 
and the ULOL are listed in Table V, and the accuracy, RSD, and precision for the four 
tricyclic antidepressants are listed in Table VI for validation on ABSciex QTRAP 3200 




Linearity was calculated by using standard calibration curves. The concentration-
response relationship of the LC-MS/MS method indicated a linear relationship between the 
concentration and response ratio with R2 values of > 0.99 for all four tricyclic 
antidepressants upon analysis on ABSciex QTRAP 3200: amitriptyline (R2 > 0.9996), 
desipramine (R2 > 0.9997), imipramine (R2 > 0.9997), and nortriptyline (R2 > 0.9996). 
The concentration-response relationship of the LC-MS/MS method indicated a linear 
relationship between the concentration and response ratio with R2 values of > 0.99 for all 
four tricyclic antidepressants upon analysis on ABSciex QTRAP 4500: amitriptyline (R2 





Accuracy and RSD 
 
The accuracy and RSD for the four TCAs were determined for within-batch and 
batch-to-batch (3 batches) for both ABSciex QTRAP 3200 and ABSciex QTRAP 4500:  
 
ABSciex QTRAP 3200 
 
For batch 1, the accuracy and RSD for the 40 ng/mL control of amitriptyline was 
calculated to be 104% (RSD 0.50) and 100% (RSD 1.83) for the 120 ng/mL concentration; 
the accuracy and RSD for the 40 ng/mL control of desipramine was determined to be 96% 
(RSD 2.18) and 99% (RSD 2.15) for the 120 ng/mL control. The accuracy and RSD for 
the 40 ng/mL control of imipramine was calculated to be 112% (RSD 3.95) and 103% 
(RSD 1.83) for the 120 ng/mL concentration; the accuracy and RSD for the 40 ng/mL 
control of nortriptyline was determined to be 96% (RSD 0.53) and 101% (RSD 2.56) for 
the 120 ng/mL control. For batch 2, the accuracy and RSD for the 40 ng/mL control of 
amitriptyline was calculated to be 104% (RSD 0.99) and 105% (RSD 3.22) for the 120 
ng/mL concentration; the accuracy and RSD for the 40 ng/mL control of desipramine was 
determined to be 102% (RSD 2.04) and 101% (RSD 1.54) for the 120 ng/mL control. The 
accuracy and RSD for the 40 ng/mL control of imipramine was calculated to be 97% (RSD 
0.76) and 98% (RSD 0.60) for the 120 ng/mL concentration; the accuracy and RSD for the 
40 ng/mL control of nortriptyline was determined to be 101% (RSD 1.04) and 101% (RSD 
1.54) for the 120 ng/mL control. For batch 3, the accuracy and RSD for the 40 ng/mL 
control of amitriptyline was calculated to be 92% (RSD 0.85) and 95% (RSD 2.79) for 
the 120 ng/mL concentration; the accuracy and RSD for the 40 ng/mL control of 
desipramine was determined to be 103% (RSD 1.66) and 100% (RSD 2.85) for the 120 
ng/mL control. The accuracy and RSD for the 40 ng/mL control of imipramine was 
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calculated to be 90% (RSD 1.30) and 99% (RSD 3.50) for the 120 ng/mL concentration; 
the accuracy and RSD for the 40 ng/mL control of nortriptyline was determined to be 
103% (RSD 0.58) and 99% (RSD 3.33) for the 120 ng/mL control. 
For the overall calculations, the accuracy for the 40 ng/mL control of amitriptyline 
was determined to be 115.95% and 105.95% for the 120 ng/mL concentration; the accuracy 
for the 40 ng/mL control of desipramine was determined to be 105.33% and 100.17% for 
the 120 ng/mL control. The accuracy for the 40 ng/mL control of imipramine was 
determined to be 103.58% and 103.34% for the 120 ng/mL concentration; the accuracy for 
the 40 ng/mL control of nortriptyline was determined to be 97.93% and 100.23% for the 
120 ng/mL control. For the overall n = 18 samples, the RSD for the 40 ng/mL control of 
amitriptyline was calculated to be 3.01 and 6.34 for the 120 ng/mL concentration; the 
RSD for the 40 ng/mL control of desipramine was determined to be 1.63 and 1.19 for the 
120 ng/mL control. The RSD for the 40 ng/mL control of imipramine was calculated to 
be 4.72 and 2.91 for the 120 ng/mL concentration; the RSD for the 40 ng/mL control of 
nortriptyline was determined to be 1.29 and 1.55 for the 120 ng/mL control. For the 
overall n = 3 batches, the RSD for the 40 ng/mL control of amitriptyline was calculated 
to be 2.64 and 5.89 for the 120 ng/mL concentration; the RSD for the 40 ng/mL control of 
desipramine was determined to be 2.30 and 2.33 for the 120 ng/mL control. The RSD for 
the 40 ng/mL control of imipramine was calculated to be 4.58 and 3.27 for the 120 ng/mL 
concentration; the RSD for the 40 ng/mL control of nortriptyline was determined to be 
1.30 and 2.76 for the 120 ng/mL control. 
 




For batch 1, the accuracy and RSD for the 40 ng/mL control of amitriptyline was 
calculated to be 95% (RSD 0.72) and 99% (RSD 1.63) for the 120 ng/mL concentration; 
the accuracy and RSD for the 40 ng/mL control of desipramine was determined to be 
100% (RSD 1.52) and 103% (RSD 3.56) for the 120 ng/mL control. The accuracy and RSD 
for the 40 ng/mL control of imipramine was calculated to be 109% (RSD 2.51) and 105% 
(RSD 1.83) for the 120 ng/mL concentration; the accuracy and RSD for the 40 ng/mL 
control of nortriptyline was determined to be 99% (RSD 0.70) and 100% (RSD 2.14) for 
the 120 ng/mL control. For batch 2, the accuracy and RSD for the 40 ng/mL control of 
amitriptyline was calculated to be 103% (RSD 1.00) and 101% (RSD 2.25) for the 120 
ng/mL concentration; the accuracy and RSD for the 40 ng/mL control of desipramine was 
determined to be 101% (RSD 0.55) and 97% (RSD 2.10) for the 120 ng/mL control. The 
accuracy and RSD for the 40 ng/mL control of imipramine was calculated to be 96% (RSD 
1.55) and 95% (RSD 4.15) for the 120 ng/mL concentration; the accuracy and RSD for the 
40 ng/mL control of nortriptyline was determined to be 94% (RSD 1.55) and 100% (RSD 
2.64) for the 120 ng/mL control. For batch 3, the accuracy and RSD for the 40 ng/mL 
control of amitriptyline was calculated to be 102% (RSD 0.88) and 100% (RSD 3.31) for 
the 120 ng/mL concentration; the accuracy and RSD for the 40 ng/mL control of 
desipramine was determined to be 99% (RSD 1.13) and 100% (RSD 2.32) for the 120 
ng/mL control. The accuracy and RSD for the 40 ng/mL control of imipramine was 
calculated to be 95% (RSD 1.14) and 100% (RSD 4.37) for the 120 ng/mL concentration; 
the accuracy and RSD for the 40 ng/mL control of nortriptyline was determined to be 
107% (RSD 1.72) and 100% (RSD 2.59) for the 120 ng/mL control. 
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For the overall calculations, the accuracy for the 40 ng/mL control of amitriptyline 
was determined to be 100.45% and 98.84% for the 120 ng/mL concentration; the accuracy 
for the 40 ng/mL control of desipramine was determined to be 102.85% and 100.42% for 
the 120 ng/mL control. The accuracy for the 40 ng/mL control of imipramine was 
determined to be 108.25% and 101.06% for the 120 ng/mL concentration; the accuracy for 
the 40 ng/mL control of nortriptyline was determined to be 97.28% and 101.43% for the 
120 ng/mL control. For the overall n = 18 samples, the RSD for the 40 ng/mL control of 
amitriptyline was calculated to be 1.76 and 1.18 for the 120 ng/mL concentration; the 
RSD for the 40 ng/mL control of desipramine was determined to be 0.38 and 3.35 for the 
120 ng/mL control. The RSD for the 40 ng/mL control of imipramine was calculated to 
be 3.38 and 6.15 for the 120 ng/mL concentration; the RSD for the 40 ng/mL control of 
nortriptyline was determined to be 2.60 and 0.19 for the 120 ng/mL control. For the 
overall n = 3 batches, the RSD for the 40 ng/mL control of amitriptyline was calculated 
to be 1.69 and 2.55 for the 120 ng/mL concentration; the RSD for the 40 ng/mL control of 
desipramine was determined to be 1.12 and 3.81 for the 120 ng/mL control. The RSD for 
the 40 ng/mL control of imipramine was calculated to be 3.32 and 6.20 for the 120 ng/mL 
concentration; the RSD for the 40 ng/mL control of nortriptyline was determined to be 




The precision for the four TCAs were calculated for within-batch (3 batches) and 





ABSciex QTRAP 3200 
 
For batch 1, the precision for the 40 ng/mL control of amitriptyline was calculated 
to be 99% and 99% for the 120 ng/mL concentration; the precision for the 40 ng/mL μg 
control of desipramine was determined to be 95% and 98% for the 120 ng/mL control. 
The precision for the 40 ng/mL control of imipramine was calculated to be 92% and 99% 
for the 120 ng/mL concentration; the precision for the 40 ng/mL μg control of 
nortriptyline was determined to be 99% and 98% for the 120 ng/mL control. For batch 2, 
the precision for the 40 ng/mL control of amitriptyline was calculated to be 98% and 98% 
for the 120 ng/mL concentration; the precision for the 40 ng/mL μg control of desipramine 
was determined to be 95% and 99% for the 120 ng/mL control. The precision for the 40 
ng/mL control of imipramine was calculated to be 98% and 100% for the 120 ng/mL 
concentration; the precision for the 40 ng/mL μg control of nortriptyline was determined 
to be 97% and 99% for the 120 ng/mL control. For batch 3, the precision for the 40 ng/mL 
control of amitriptyline was calculated to be 98% and 98% for the 120 ng/mL 
concentration; the precision for the 40 ng/mL μg control of desipramine was determined 
to be 96% and 98% for the 120 ng/mL control. The precision for the 40 ng/mL control of 
imipramine was calculated to be 97% and 97% for the 120 ng/mL concentration; the 
precision for the 40 ng/mL μg control of nortriptyline was determined to be 99% and 97% 
for the 120 ng/mL control.  
For the overall 18 samples, the precision for the 40 ng/mL control of amitriptyline 
was calculated to be 94% and 95% for the 120 ng/mL concentration; the precision for the 
40 ng/mL control of desipramine was determined to be 96% and 99% for the 120 ng/mL 
control. The precision for the 40 ng/mL control of imipramine was calculated to be 89% 
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and 98% for the 120 ng/mL concentration; the precision for the 40 ng/mL control of 
nortriptyline was determined to be 97% and 99% for the 120 ng/mL control.  For the 
overall n = 3 batches, the precision for the 40 ng/mL control of amitriptyline was 
calculated to be 94% and 95% for the 120 ng/mL concentration; the precision for the 40 
ng/mL control of desipramine was determined to be 95% and 98% for the 120 ng/mL 
control. The precision for the 40 ng/mL control of imipramine was calculated to be 89% 
and 97% for the 120 ng/mL concentration; the precision for the 40 ng/mL control of 
nortriptyline was determined to be 97% and 98% for the 120 ng/mL control. 
 
ABSciex QTRAP 4500 
  
For batch 1, the precision for the 40 ng/mL control of amitriptyline was calculated 
to be 98% and 99% for the 120 ng/mL concentration; the precision for the 40 ng/mL μg 
control of desipramine was determined to be 96% and 97% for the 120 ng/mL control. 
The precision for the 40 ng/mL control of imipramine was calculated to be 95% and 99% 
for the 120 ng/mL concentration; the precision for the 40 ng/mL μg control of 
nortriptyline was determined to be 98% and 98% for the 120 ng/mL control. For batch 2, 
the precision for the 40 ng/mL control of amitriptyline was calculated to be 98% and 98% 
for the 120 ng/mL concentration; the precision for the 40 ng/mL μg control of desipramine 
was determined to be 99% and 98% for the 120 ng/mL control. The precision for the 40 
ng/mL control of imipramine was calculated to be 96% and 96% for the 120 ng/mL 
concentration; the precision for the 40 ng/mL μg control of nortriptyline was determined 
to be 96% and 98% for the 120 ng/mL control. For batch 3, the precision for the 40 ng/mL 
control of amitriptyline was calculated to be 98% and 97% for the 120 ng/mL 
concentration; the precision for the 40 ng/mL μg control of desipramine was determined 
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to be 97% and 98% for the 120 ng/mL control. The precision for the 40 ng/mL control of 
imipramine was calculated to be 97% and 96% for the 120 ng/mL concentration; the 
precision for the 40 ng/mL μg control of nortriptyline was determined to be 96% and 98% 
for the 120 ng/mL control.  
For the overall 18 samples, the precision for the 40 ng/mL control of amitriptyline 
was calculated to be 96% and 99% for the 120 ng/mL concentration; the precision for the 
40 ng/mL control of desipramine was determined to be 99% and 97% for the 120 ng/mL 
control. The precision for the 40 ng/mL control of imipramine was calculated to be 92% 
and 95% for the 120 ng/mL concentration; the precision for the 40 ng/mL control of 
nortriptyline was determined to be 93% and 100% for the 120 ng/mL control.  For the 
overall n = 3 batches, the precision for the 40 ng/mL control of amitriptyline was 
calculated to be 96% and 98% for the 120 ng/mL concentration; the precision for the 40 
ng/mL control of desipramine was determined to be 97% and 97% for the 120 ng/mL 
control. The precision for the 40 ng/mL control of imipramine was calculated to be 92% 
and 95% for the 120 ng/mL concentration; the precision for the 40 ng/mL control of 








RESULTS AND DISCUSSION 
An LC-MS/MS method was developed and validated for the quantitation of 
amitriptyline, desipramine, imipramine, and nortriptyline in human plasma samples. The 
structures of the tricyclic antidepressants are shown in Figure 1. The LC conditions (Table 
I), the time program (Table II), and the mass spectrometer (MS) parameters (Table III) 
were all optimized in order to achieve the highest sensitivity of the tricyclic 
antidepressants’ peaks. A chromatogram of a calibrator at 25 ng/mL (125 pg on the 
column) analyzed on the ABSciex QTRAP 3200 is shown in Figure 2, and a chromatogram 
of a calibrator at 25 ng/mL (50 pg on the column) analyzed on the ABSciex QTRAP 4500 
is shown in Figure 3. In addition, a chromatogram of an unknown sample analyzed on the 
ABSciex QTRAP 3200 is shown in Figure 4, and a chromatogram of an unknown sample 
analyzed on the ABSciex QTRAP 4500 is shown in Figure 5. The ions monitored for the 
four TCAs and internal standards can be found in Table IV.  
The LOD and LOQ for all four TCAs was calculated to be 1.0 ng/mL, while the 
ULOL for the TCAs was identified to be 400 ng/mL. The LOD, LOQ, and ULOL of the 
TCAs are shown in Table V.  
The method was validated using 6 replicates of two concentrations (40 ng/mL and 
120 ng/mL) over 3 days. The individual and overall accuracies, precisions, and RSD values 




The developed and validated LC-MS/MS method was applied for the analysis of 
over 350 different customer human plasma samples. The four tricyclic antidepressants 
were identified in each plasma sample based on their specific MRMs (Table IV). There are 
a total of 52 samples identified positive for amitriptyline, 287 samples positive for 
nortriptyline, 18 samples positive for desipramine, and 12 samples positive for imipramine. 
These results are shown graphically in Figure 6.  
Hence, the developed and validated LC-MS/MS method was accurate and sensitive 















Table I: LC Conditions. 
LC Conditions 
Column Synergi 4µ Hydro-RP 80A 150 x 3.00mm 
Flow Binary, 0.65 mL/min total 
Injection Volume (µL) 2.0 µL (4500) / 5.0 µL (3200)  
Column Oven Temperature 30° C 
Mobile Phase A 0.1% Formic Acid in Water 






















Table II: LC Time Program. 
Time (min) Module Events % 
1.20 Pumps Pump B Conc 20 
5.00 Pumps Pump B Conc 60 
8.00 Pumps Pump B Conc 80 
8.50 Pumps Pump B Conc 95 
12.00 Pumps Pump B Conc 95 
12.50 Pumps Pump B Conc 20 






















Table III: Mass Spectrometer (MS) Parameters. 
MS Parameters 
Mass Spectrometer AB Sciex QTRAP 3200/4500 
Scan Type MRM 
Mode Positive 
Ion Source Turbo Spray (ESI) 
Curtain Gas 40 lpm (N2) 
Collision Gas Medium (N2) 
IonSpray Voltage 4000.0 V 
Temperature 600.0° C 
Ion Source Gas 1 60.0 lpm (Air) 



































Amitriptyline 1 277 278.480 233.060 50.0 46 11 19 4 
Amitriptyline 2 277 278.480 191.105 50.0 46 11 25 4 
Amitriptyline-d3 1 280 281.090 191.088 50.0 56 4 33 4 
Amitriptyline-d3 2 280 281.090 117.023 50.0 20 10 31 4 
Desipramine 1 266 267.078 208.100 50.0 41 6 47 4 
Desipramine 3 266 267.078 72.020 50.0 41 6 29 4 
Desipramine-d3 1 269 269.910 208.050 50.0 41 5 31 4 
Desipramine-d3 3 269 269.910 75.030 50.0 41 5 25 4 
Imipramine 1 280 281.030 208.150 50.0 46 10 35 4 
Imipramine 3 280 281.030 86.050 50.0 46 10 23 4 
Imipramine-d3 1 283 284.110 208.400 50.0 46 3.5 41 4 
Imipramine-d3 3 283 284.110 89.050 50.0 46 3.5 23 4 
Nortriptyline 1 263 264.060 233.060 50.0 41 6 17 4 
Nortriptyline 2 263 264.060 117.030 50.0 41 6 25 4 
Nortriptyline-d3 1 266 267.323 233.200 50.0 41 12 17 6 
Nortriptyline-d3 2 266 267.323 117.029 50.0 41 12 21 4 
Q1 and Q3 m/z: Ion filter applied to Q1 and Q3 quadrupoles, Dwell: length of time for 
each MRM (combination of potentials) before changing to next MRM, DP: 













Table V: LOD, LOQ, and uLOL of Amitriptyline, Desipramine, Imipramine and 
Nortriptyline.  
 Amitriptyline Desipramine Imipramine Nortriptyline 
LOD (ng/mL) 1.0 1.0 1.0 1.0 
LOQ (ng/mL) 1.0 1.0 1.0 1.0 





















Table VI. Within-Batch and Overall Batch Mean, RSD, Accuracy, and Precision 
for Amitriptyline, Desipramine, Imipramine, and Nortriptyline for Validation on 
ABSciex QTRAP 3200. 
AMTRIPTYLINE 
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
47.27 102% Mean : 48.05 125.7 99% Mean : 127.30 
48.02 104% SD : 0.50 126.9 100% SD : 1.83 
48.34 104% Accuracy : 104% 124.9 99% Accuracy : 100% 
47.83 103% Precision : 99% 129.6 102% Precision : 99% 
48.76 105% %CV : 1.0% 129.1 102% %CV : 1.4% 
48.08 104%   127.6 101%   
Batch 2 
47.00 101% Mean : 48.19 128.9 102% Mean : 132.82 
48.61 105% SD : 0.99 133.0 105% SD : 3.22 
49.17 106% Accuracy : 104% 136.8 108% Accuracy : 105% 
48.88 105% Precision : 98% 136.4 108% Precision : 98% 
46.88 101% %CV : 2.1% 130.5 103% %CV : 2.4% 
48.59 105%   131.4 104%   
Batch 3 
43.00 93% Mean : 42.90 120.0 95% Mean : 120.17 
41.70 90% SD : 0.85 123.0 97% SD : 2.79 
43.70 94% Accuracy : 92% 124.0 98% Accuracy : 95% 
42.60 92% Precision : 98% 119.0 94% Precision : 98% 
44.00 95% %CV : 2.0% 118.0 93% %CV : 2.3% 
42.40 91%   117.0 92%   
         
 Overall 40 120   Avg SD 
  Mean : 46.38 126.76  RT : 6.07 0.05 
 
n = 1 batches 
SD : 3.01 6.34  IS RT : 6.06 0.05 
 Precision : 94% 95%  IS Area : 1124822 210521 
 %CV : 6.5% 5.0%     
 
n = 18 samples 
SD : 2.64 5.89     
 Precision : 94% 95%     




         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
38.98 93% Mean : 40.28 119.6 100% Mean : 119.19 
38.00 90% SD : 2.18 119.3 99% SD : 2.15 
38.44 91% Accuracy : 96% 122.2 102% Accuracy : 99% 
42.04 100% Precision : 95% 116.2 97% Precision : 98% 
40.73 97% %CV : 5.4% 117.4 98% %CV : 1.8% 
43.47 103%   120.4 100%   
Batch 2 
44.53 106% Mean : 42.77 120.2 100% Mean : 121.51 
45.13 107% SD : 2.04 119.3 99% SD : 1.54 
43.96 104% Accuracy : 102% 121.7 101% Accuracy : 101% 
41.23 98% Precision : 95% 123.5 103% Precision : 99% 
41.68 99% %CV : 4.8% 122.7 102% %CV : 1.3% 
40.10 95%   121.6 101%   
Batch 3 
43.04 102% Mean : 43.34 121.8 101% Mean : 119.89 
41.91 99% SD : 1.66 124.3 103% SD : 2.85 
45.96 109% Accuracy : 103% 116.8 97% Accuracy : 100% 
41.32 98% Precision : 96% 117.4 98% Precision : 98% 
43.71 104% %CV : 3.8% 118.8 99% %CV : 2.4% 
44.09 105%   120.3 100%   
         
 Overall 40 120   Avg SD 
  Mean : 42.13 120.20  RT : 5.77 0.04 
 
n = 1 batches 
SD : 1.63 1.19  IS RT : 5.76 0.04 
 Precision : 96% 99%  IS Area : 1827365 1389687 
 %CV : 3.9% 1.0%     
 
n = 18 samples 
SD : 2.30 2.33     
 Precision : 95% 98%     
 %CV : 5.5% 1.9%     






         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
38.56 93% Mean : 46.60 125.7 101% Mean : 127.30 
48.02 116% SD : 3.95 126.9 102% SD : 1.83 
48.34 117% Accuracy : 112% 124.9 101% Accuracy : 103% 
47.83 115% Precision : 92% 129.6 104% Precision : 99% 
48.76 118% %CV : 8.5% 129.1 104% %CV : 1.4% 
48.08 116%   127.6 103%   
Batch 2 
40.12 97% Mean : 40.33 121.5 98% Mean : 121.77 
41.61 100% SD : 0.76 122.1 98% SD : 0.60 
40.02 97% Accuracy : 97% 122.7 99% Accuracy : 98% 
39.35 95% Precision : 98% 121.9 98% Precision : 100% 
40.67 98% %CV : 1.9% 121.5 98% %CV : 0.5% 
40.22 97%   121.0 98%   
Batch 3 
37.69 91% Mean : 37.35 124.5 100% Mean : 122.95 
38.35 93% SD : 1.30 124.0 100% SD : 3.50 
36.23 87% Accuracy : 90% 122.2 99% Accuracy : 99% 
39.17 95% Precision : 97% 128.4 104% Precision : 97% 
36.94 89% %CV : 3.5% 118.5 96% %CV : 2.8% 
35.75 86%   120.2 97%   
         
 Overall 40 120   Avg SD 
  Mean : 41.43 124.01  RT : 5.90 0.04 
 
n = 1 batches 
SD : 4.72 2.91  IS RT : 5.90 0.04 
 Precision : 89% 98%  IS Area : 2771770 2412145 
 %CV : 11.4% 2.3%     
 
n = 18 samples 
SD : 4.58 3.27     
 Precision : 89% 97%     







         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
37.38 95% Mean : 37.74 122.1 102% Mean : 121.01 
37.31 95% SD : 0.53 124.6 104% SD : 2.56 
37.48 96% Accuracy : 96% 120.3 100% Accuracy : 101% 
38.66 99% Precision : 99% 120.4 100% Precision : 98% 
37.49 96% %CV : 1.4% 121.8 101% %CV : 2.1% 
38.11 97%   116.8 97%   
Batch 2 
39.18 100% Mean : 39.51 121.6 101% Mean : 121.34 
38.19 98% SD : 1.04 123.2 102% SD : 1.54 
39.03 100% Accuracy : 101% 122.9 102% Accuracy : 101% 
40.01 102% Precision : 97% 119.2 99% Precision : 99% 
39.40 101% %CV : 2.6% 120.8 100% %CV : 1.3% 
41.26 105%   120.3 100%   
Batch 3 
41.00 105% Mean : 40.25 116.0 96% Mean : 118.50 
39.90 102% SD : 0.58 121.0 101% SD : 3.33 
40.40 103% Accuracy : 103% 113.0 94% Accuracy : 99% 
40.40 103% Precision : 99% 121.0 101% Precision : 97% 
40.50 103% %CV : 1.4% 119.0 99% %CV : 2.8% 
39.30 100%   121.0 101%   
         
 Overall 40 120   Avg SD 
  Mean : 39.17 120.28  RT : 5.92 0.05 
 
n = 1 batches 
SD : 1.29 1.55  IS RT : 5.92 0.04 
 Precision : 97% 99%  IS Area : 848037 307930 
 %CV : 3.3% 1.3%     
 
n = 18 samples 
SD : 1.30 2.76     






Table VII: Within-Batch Mean and Overall Batch RSD, Accuracy, and Precision 
for Amitriptyline, Desipramine, Imipramine, and Nortriptyline for Validation on 
ABSciex QTRAP 4500. 
AMTRIPTYLINE  
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
38.60 96% Mean : 38.17 119.0 100% Mean : 117.33 
38.50 96% SD : 0.72 119.0 100% SD : 1.63 
38.80 97% Accuracy : 95% 116.0 98% Accuracy : 99% 
37.40 93% Precision : 98% 118.0 99% Precision : 99% 
38.60 96% %CV : 1.9% 115.0 97% %CV : 1.4% 
37.10 92%   117.0 99%   
Batch 2 
41.40 103% Mean : 41.42 116.0 98% Mean : 119.67 
40.70 101% SD : 1.00 120.0 101% SD : 2.25 
41.40 103% Accuracy : 103% 120.0 101% Accuracy : 101% 
42.20 105% Precision : 98% 119.0 100% Precision : 98% 
40.00 100% %CV : 2.4% 123.0 104% %CV : 1.9% 
42.80 107%   120.0 101%   
Batch 3 
41.30 103% Mean : 40.97 116.0 98% Mean : 118.83 
39.60 99% SD : 0.88 121.0 102% SD : 3.31 
41.20 103% Accuracy : 102% 123.0 104% Accuracy : 100% 
41.10 102% Precision : 98% 119.0 100% Precision : 97% 
40.40 101% %CV : 2.2% 120.0 101% %CV : 2.8% 
42.20 105%   114.0 96%   
         
 Overall 40 120   Avg SD 
  Mean : 40.18 118.61  RT : 5.61 0.01 
 
n = 1 batches 
SD : 1.76 1.18  IS RT : 5.59 0.01 
 Precision : 96% 99%  IS Area : 6143580 1104529 
 %CV : 4.4% 1.0%     
 
n = 18 samples 
SD : 1.69 2.55     
 Precision : 96% 98%     




         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
43.30 105% Mean : 41.15 128.0 106% Mean : 123.67 
42.10 102% SD : 1.52 118.0 98% SD : 3.56 
39.20 95% Accuracy : 100% 123.0 102% Accuracy : 103% 
40.60 99% Precision : 96% 123.0 102% Precision : 97% 
39.90 97% %CV : 3.7% 123.0 102% %CV : 2.9% 
41.80 102%   127.0 105%   
Batch 2 
41.20 100% Mean : 41.52 119.0 99% Mean : 117.00 
41.40 101% SD : 0.55 116.0 96% SD : 2.10 
41.10 100% Accuracy : 101% 117.0 97% Accuracy : 97% 
41.40 101% Precision : 99% 115.0 95% Precision : 98% 
41.40 101% %CV : 1.3% 120.0 100% %CV : 1.8% 
42.60 104%   115.0 95%   
Batch 3 
42.10 102% Mean : 40.77 118.0 98% Mean : 120.83 
40.30 98% SD : 1.13 120.0 100% SD : 2.32 
39.30 96% Accuracy : 99% 124.0 103% Accuracy : 100% 
41.30 100% Precision : 97% 119.0 99% Precision : 98% 
41.80 102% %CV : 2.8% 123.0 102% %CV : 1.9% 
39.80 97%   121.0 100%   
         
 Overall 40 120   Avg SD 
  Mean : 41.14 120.50  RT : 5.29 0.01 
 
n = 1 batches 
SD : 0.38 3.35  IS RT : 5.28 0.01 
 Precision : 99% 97%  IS Area : 8989907 6577508 
 %CV : 0.9% 2.8%     
 
n = 18 samples 
SD : 1.12 3.81     
 Precision : 97% 97%     







         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
42.10 97% Mean : 47.19 125.7 104% Mean : 127.30 
48.02 111% SD : 2.51 126.9 105% SD : 1.83 
48.34 112% Accuracy : 109% 124.9 103% Accuracy : 105% 
47.83 110% Precision : 95% 129.6 107% Precision : 99% 
48.76 113% %CV : 5.3% 129.1 106% %CV : 1.4% 
48.08 111%   127.6 105%   
Batch 2 
41.50 96% Mean : 41.65 112.0 92% Mean : 115.00 
42.70 99% SD : 1.55 118.0 97% SD : 4.15 
41.50 96% Accuracy : 96% 114.0 94% Accuracy : 95% 
43.60 101% Precision : 96% 122.0 101% Precision : 96% 
41.60 96% %CV : 3.7% 112.0 92% %CV : 3.6% 
39.00 90%   112.0 92%   
Batch 3 
40.80 94% Mean : 41.07 126.0 104% Mean : 121.50 
41.00 95% SD : 1.14 126.0 104% SD : 4.37 
42.30 98% Accuracy : 95% 124.0 102% Accuracy : 100% 
41.70 96% Precision : 97% 116.0 96% Precision : 96% 
41.60 96% %CV : 2.8% 119.0 98% %CV : 3.6% 
39.00 90%   118.0 97%   
         
 Overall 40 120   Avg SD 
  Mean : 43.30 121.27  RT : 5.43 0.01 
 
n = 1 batches 
SD : 3.38 6.15  IS RT : 5.42 0.01 
 Precision : 92% 95%  IS Area : 15973139 14854877 
 %CV : 7.8% 5.1%     
 
n = 18 samples 
SD : 3.32 6.20     
 Precision : 92% 95%     







         
 40 120 
Expected Conc.: 40 ng/mL 120 ng/mL 
 Conc. Accuracy Within Batch Conc. Accuracy Within Batch 
Batch 1 
38.40 99% Mean : 38.60 123.0 101% Mean : 121.83 
39.30 101% SD : 0.70 119.0 98% SD : 2.14 
37.60 97% Accuracy : 99% 122.0 100% Accuracy : 100% 
38.10 98% Precision : 98% 120.0 99% Precision : 98% 
38.80 100% %CV : 1.8% 122.0 100% %CV : 1.8% 
39.40 101%   125.0 103%   
Batch 2 
37.40 96% Mean : 36.48 125.0 103% Mean : 121.83 
39.10 100% SD : 1.55 121.0 99% SD : 2.64 
36.50 94% Accuracy : 94% 118.0 97% Accuracy : 100% 
35.30 91% Precision : 96% 123.0 101% Precision : 98% 
35.10 90% %CV : 4.2% 120.0 99% %CV : 2.2% 
35.50 91%   124.0 102%   
Batch 3 
42.90 110% Mean : 41.65 123.0 101% Mean : 121.50 
40.90 105% SD : 1.72 120.0 99% SD : 2.59 
43.40 112% Accuracy : 107% 124.0 102% Accuracy : 100% 
38.70 99% Precision : 96% 123.0 101% Precision : 98% 
42.60 109% %CV : 4.1% 117.0 96% %CV : 2.1% 
41.40 106%   122.0 100%   
         
 Overall 40 120   Avg SD 
  Mean : 38.91 121.72  RT : 5.47 0.01 
 
n = 1 batches 
SD : 2.60 0.19  IS RT : 5.46 0.01 
 Precision : 93% 100%  IS Area : 6308519 3150816 
 %CV : 6.7% 0.2%     
 
n = 18 samples 
SD : 2.55 2.32     
 Precision : 93% 98%     





Figure 2: Representative Chromatogram of a Low Control (25 ng/mL) (125 pg on 













XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 9 (S2979 VVL) of S2979.wiff (Turbo Spray) Max. 4.2e4 cps.








 Polarity/Scan Type: Positive MRM
 Post RepairTesting
 *Elsohly Labs
 *3200 QTrap S/N AF14970708
 Acq. Time: 16:05
 Acq. Date: Monday, February 11, 2019
 Acq. File: S2979.wiff
XIC of +MRM (24 pairs): 278.480/233.060 Da ID: AMT... Max. 1.5e4 cps.












XIC of +MRM (24 pairs): 281.090/191.088 Da ID: D3-A... Max. 1.5e5 cps.












XIC of +MRM (24 pairs): 278.480/191.105 Da ID: AM... Max. 9100.0 cps.












XIC of +MRM (24 pairs): 281.090/117.023 Da ID: D3-A... Max. 2.1e5 cps.












XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NOR... Max. 4.2e4 cps.












XIC of +MRM (24 pairs): 267.323/233.200 Da ID: D3-N... Max. 2.0e5 cps.












XIC of +MRM (24 pairs): 264.060/117.030 Da ID: NOR... Max. 3.6e4 cps.











XIC of +MRM (24 pairs): 267.323/117.029 Da ID: D3-N... Max. 1.2e5 cps.













XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 9 (S2979 VVL) of S2979.wiff (Turbo Spray) Max. 4.2e4 cps.








 Polarity/Scan Type: Positive MRM
 Post RepairTesting
 *Elsohly Labs
 *3200 QTrap S/N AF14970708
 Acq. Time: 16:05
 Acq. Date: Monday, February 11, 2019
 Acq. File: S2979.wiff
XIC of +MRM (24 pairs): 281.030/208.150 Da ID: IMIP... Max. 1.2e4 cps.












XIC of +MRM (24 pairs): 284.110/208.400 Da ID: D3-I... Max. 7.3e4 cps.












XIC of +MRM (24 pairs): 281.030/86.050 Da ID: IMIPR... Max. 1.1e5 cps.












XIC of +MRM (24 pairs): 284.110/89.050 Da ID: D3-IM... Max. 9.0e5 cps.












XIC of +MRM (24 pairs): 267.078/208.100 Da ID: DE... Max. 5680.0 cps.













XIC of +MRM (24 pairs): 269.910/208.050 Da ID: D3-D... Max. 9.9e4 cps.












XIC of +MRM (24 pairs): 267.078/72.020 Da ID: DESI... Max. 1.1e5 cps.












XIC of +MRM (24 pairs): 269.910/75.030 Da ID: D3-D... Max. 6.7e5 cps.














Figure 3: Representative Chromatogram of a Low Control (25 ng/mL) (50 pg on 













XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 7 (S2989 VVL 25NG-ML) of S2989.wiff (Turbo Spr... Max. 4.2e5 cps.







 Analyst Version: 1.6.3
 Printing Date: Tuesday, February 4, 2020
 *BI20681206
 *Qtrap4500 Post-PM
 Acq. Date: Saturday, February 23, 2019
 Acq. File: S2989.wiff
 Acq. Time: 02:10
XIC of +MRM (24 pairs): 278.480/233.060 Da ID: AMT... Max. 1.5e5 cps.









XIC of +MRM (24 pairs): 281.090/191.088 Da ID: D3-A... Max. 1.1e6 cps.









XIC of +MRM (24 pairs): 278.480/191.105 Da ID: AMT... Max. 4.8e4 cps.








XIC of +MRM (24 pairs): 281.090/117.023 Da ID: D3-A... Max. 1.5e6 cps.









XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NOR... Max. 4.2e5 cps.









XIC of +MRM (24 pairs): 267.323/233.200 Da ID: D3-N... Max. 2.4e6 cps.









XIC of +MRM (24 pairs): 264.060/117.030 Da ID: NOR... Max. 1.9e5 cps.










XIC of +MRM (24 pairs): 267.323/117.029 Da ID: D3-N... Max. 9.4e5 cps.











XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 7 (S2989 VVL 25NG-ML) of S2989.wiff (Turbo Spr... Max. 4.2e5 cps.






 Analyst Version: 1.6.3
 Printing Date: Tuesday, February 4, 2020
 *BI20681206
 *Qtrap4500 Post-PM
 Acq. Date: Saturday, February 23, 2019
 Acq. File: S2989.wiff
 Acq. Time: 02:10
XIC of +MRM (24 pairs): 281.030/208.150 Da ID: IMIP... Max. 9.5e4 cps.









XIC of +MRM (24 pairs): 284.110/208.400 Da ID: D3-I... Max. 2.9e5 cps.










XIC of +MRM (24 pairs): 281.030/86.050 Da ID: IMIPR... Max. 9.4e5 cps.










XIC of +MRM (24 pairs): 284.110/89.050 Da ID: D3-IMI... Max. 5.8e6 cps.









XIC of +MRM (24 pairs): 267.078/208.100 Da ID: DESI... Max. 3.3e4 cps.









XIC of +MRM (24 pairs): 269.910/208.050 Da ID: D3-D... Max. 6.0e5 cps.









XIC of +MRM (24 pairs): 267.078/72.020 Da ID: DESIP... Max. 5.4e5 cps.









XIC of +MRM (24 pairs): 269.910/75.030 Da ID: D3-DE... Max. 3.4e6 cps.












Figure 4: Representative Chromatogram of a Real Sample Analyzed on ABSciex 













XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 50 (S2979 DP 893) of S2979.wiff (Turbo Spray) Max. 3.8e4 cps.







 Polarity/Scan Type: Positive MRM
 Post RepairTesting
 *Elsohly Labs
 *3200 QTrap S/N AF14970708
 Acq. Time: 11:39
 Acq. Date: Tuesday, February 12, 2019
 Acq. File: S2979.wiff
XIC of +MRM (24 pairs): 278.480/233.060 Da ID: AMT... Max. 2.4e4 cps.













XIC of +MRM (24 pairs): 281.090/191.088 Da ID: D3-A... Max. 1.3e5 cps.













XIC of +MRM (24 pairs): 278.480/191.105 Da ID: AMT... Max. 1.1e4 cps.













XIC of +MRM (24 pairs): 281.090/117.023 Da ID: D3-A... Max. 1.7e5 cps.












XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NOR... Max. 3.8e4 cps.











XIC of +MRM (24 pairs): 267.323/233.200 Da ID: D3-N... Max. 2.2e5 cps.












XIC of +MRM (24 pairs): 264.060/117.030 Da ID: NOR... Max. 2.7e4 cps.













XIC of +MRM (24 pairs): 267.323/117.029 Da ID: D3-N... Max. 1.3e5 cps.















Figure 5. Representative Chromatogram of a Real Sample Analyzed on ABSciex 













XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NORTRIPTYLINE 1 from Sample 59 (S3004 DQ 512) of S3004.wiff (Turbo Spray) Max. 5.1e5 cps.







 Analyst Version: 1.6.3
 Printing Date: Tuesday, February 4, 2020
 *BI20681206
 *Qtrap4500 Post-PM
 Acq. Date: Friday, March 15, 2019
 Acq. File: S3004.wiff
 Acq. Time: 21:25
XIC of +MRM (24 pairs): 278.480/233.060 Da ID: AMT... Max. 4.9e5 cps.








XIC of +MRM (24 pairs): 281.090/191.088 Da ID: D3-A... Max. 5.9e5 cps.









XIC of +MRM (24 pairs): 278.480/191.105 Da ID: AMT... Max. 1.6e5 cps.










XIC of +MRM (24 pairs): 281.090/117.023 Da ID: D3-A... Max. 7.0e5 cps.










XIC of +MRM (24 pairs): 264.060/233.060 Da ID: NOR... Max. 5.1e5 cps.









XIC of +MRM (24 pairs): 267.323/233.200 Da ID: D3-N... Max. 1.4e6 cps.










XIC of +MRM (24 pairs): 264.060/117.030 Da ID: NOR... Max. 2.2e5 cps.










XIC of +MRM (24 pairs): 267.323/117.029 Da ID: D3-N... Max. 6.2e5 cps.










I  f  (  ir ): . /233. 6   I : TRIPTYLINE 1 from Sample 56 (S3004 DQ 511) of S3004.wiff (Turbo Spray) Max. 2580.0 .






 Analyst Version: 1.6.3
 Printing Date: Tuesday, February 4, 2020
 *BI20681206
 *Qtrap4500 Post-PM
 Acq. Date: Friday, March 15, 2019
 Acq. File: S3004.wiff
 Acq. Time: 20:36
XIC of +MRM (24 pairs): 281.030/208.150 Da ID: IMIP... Max. 3.7e5 cps.








XIC of +MRM (24 pairs): 284.110/208.400 Da ID: D3-I... Max. 1.6e5 cps.










XIC of +MRM (24 pairs): 281.030/86.050 Da ID: IMIPR... Max. 3.5e6 cps.









XIC of +MRM (24 pairs): 284.110/89.050 Da ID: D3-IMI... Max. 3.4e6 cps.









XIC of +MRM (24 pairs): 267.078/208.100 Da ID: DESI... Max. 1.1e5 cps.









XIC of +MRM (24 pairs): 269.910/208.050 Da ID: D3-D... Max. 3.2e5 cps.








XIC of +MRM (24 pairs): 267.078/72.020 Da ID: DESIP... Max. 1.6e6 cps.










XIC of +MRM (24 pairs): 269.910/75.030 Da ID: D3-DE... Max. 1.7e6 cps.


















































An LC-MS/MS method was successfully validated for the analysis of amitriptyline, 
desipramine, imipramine, and nortriptyline in human plasma. The method was 
reproducible for all four of the tricyclic antidepressants and was applied to over 350 human 
plasma samples. It was determined that the presence of amitriptyline in samples coincided 
with the presence of nortriptyline in the same samples; these samples did not include 
desipramine or imipramine. In the samples with either desipramine or imipramine, no other 
TCA was identified. The developed and validated LC-MS/MS method was robust, 
reproducible, and highly sensitive for the determination of low levels of the TCAs in human 
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